Dr. Steven Rowe the first clinician to inject VX-770 for research in this country says:
".....Dr. Steven Rowe of the University of Alabama, Birmingham and also an investigator in the VX-809/Kalydeco study, had a similar view:
"It's exciting to see the combination treatment come to fruition. It's a phase II design and we've been fooled before but this looks pretty convincing."
Rowe on what a 6% improvement in lung function means to a CF patient:
"FEV1 is a speedometer for CF patients. It's what they check every time they come to clinic and so, even small changes mean a fair amount to patients. These results compare favorably to many other drugs that have been approved and widely used for CF, so I think people would be excited about it."